7 Result(s)

Article

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

Activity estimates should be accurately evaluated in phase 2 clinical trials to ensure appropriate decisions about proceeding to phase 3 trials. RECIST v1.1. progression-free survival (PFS) is a common endpoin...

Katrin M. Sjoquist, Andrew Martin… in Journal of Cancer Research and Clinical On… (2023)

Article

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

Advanced gastro-oesophageal cancer (AGOC) carries a poor prognosis. No standard of care treatment options are available after first and second-line therapies. Regorafenib is an oral multi-targeted tyrosine kin...

Lyn Ley Lam, Nick Pavlakis, Kohei Shitara, Katrin M. Sjoquist… in BMC Cancer (2023)

Article

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer

Among patients with non-metastatic pancreatic cancer, 80% have high-risk, borderline resectable or locally advanced cancer, with a 5-year overall survival of 12%. MASTERPLAN evaluates the safety and activity o...

Andrew Oar, Mark Lee, Hien Le, Kate Wilson, Chris Aiken, Lorraine Chantrill… in BMC Cancer (2021)

Article

Challenges of international oncology trial collaboration—a call to action

International collaboration in oncology trials has the potential to enhance clinical trial activity by expediting the recruitment of large patient populations, testing treatments in diverse populations and fac...

Monica Tang, Heikki Joensuu, Robert J. Simes, Timothy J. Price… in British Journal of Cancer (2019)

Article

Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial

This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.

Niall C Tebbutt, Timothy J Price, Danielle A Ferraro… in British Journal of Cancer (2016)

Article

Gastric cancer: past progress and present challenges

Katrin M. Sjoquist, John R. Zalcberg in Gastric Cancer (2015)